Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates generally to the detection and treatment of Ehrlichia infection.
• the invention is related to polypeptides comprising an Ehrlichia antigen and the use of such polypeptides for the serodiagnosis and treatment of Human granulocytic ehrlichiosis (HGE).
• HGE Human granulocytic ehrlichiosis
• HGE Human granulocytic ehrlichiosis
• a rodent bacterium which is generally transmitted to humans by the same tick that is responsible for the transmission of Lyme disease and babesiosis, thereby leading to the possibility of co-infection with Lyme disease, babesiosis and HGE from a single tick bite.
• the bacterium that causes HGE is believed to be quite widespread in parts of the northeastern United States and has been detected in parts of Europe. While the number of reported cases of HGE infection is increasing rapidly, infection with Ehrlichia, including co-infection with Lyme disease, often remains undetected for extended periods of time. HGE is a potentially fatal disease, with the risk of death increasing if appropriate treatment is delayed beyond the first few days after symptoms occur. In contrast, deaths from Lyme disease and babesiosis are relatively rare.
• HGE human epidermatitis
• Lyme disease Lyme disease
• babesiosis babesiosis
• penicillin's such as doxycycline and amoxicillin
• anti-malarial drugs being preferred for the treatment of babesiosis
• tetracycline being preferred for the treatment of ehrlichiosis.
• Accurate and early diagnosis of Ehrlichia infection is thus critical but methods currently employed for diagnosis are problematic.
• polypeptides comprising an immunogenic portion of an Ehrlichia antigen, particularly one associated with HGE, or a variant of such an antigen that differs only in conservative substitutions and/or modifications.
• the antigen comprises an amino acid sequence encoded by a DNA sequence selected from the group consisting of (a) sequences recited in SEQ ID NO: 1-3, 5, 7, 16, 20, 34, 39-49; (b) the complements of said sequences; and (c) sequences that hybridize to a sequence of (a) or (b) under moderately stringent conditions.
• the present invention provides an antigenic epitope of an Ehrlichia antigen comprising an amino acid sequence selected from the group consisting of sequences recited in SEQ ID NO: 30 and 51, together with polypeptides comprising at least two such antigenic epitopes. the epitopes being contiguous.
• DNA sequences encoding the above polypeptides are also provided.
• recombinant expression vectors comprising one or more of these DNA sequences and host cells transformed or transfected with such expression vectors are also provided.
• the present invention provides fusion proteins comprising either a first and a second inventive polypeptide, a first and a second inventive antigenic epitope, or, alternatively, an inventive polypeptide and an inventive antigenic epitope.
• a fusion protein comprising an amino acid sequence provided in SEQ ID NO: 85 is provided.
• the method comprises: (a) contacting a biological sample with at least one of the above polypeptides, antigenic epitopes or fusion proteins; and (b) detecting in the sample the presence of antibodies that bind to the polypeptide, antigenic epitope or fusion protein, thereby detecting Ehrlichia infection in the biological sample.
• suitable biological samples include whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid and urine.
• the diagnostic kits comprise one or more of the above polypeptides, antigenic epitopes or fusion proteins in combination with a detection reagent.
• the present invention also provides methods for detecting Ehrlichia infection comprising: (a) obtaining a biological sample from a patient; (b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, at least one of the oligonucleotide primers being specific for a DNA sequence encoding the above polypeptides; and (c) detecting in the sample a DNA sequence that amplifies in the presence of the oligonucleotide primers.
• the oligonucleotide primer comprises at least about 10 contiguous nucleotides of a DNA sequence encoding the above polypeptides.
• the present invention provides a method for detecting Ehrlichia infection in a patient comprising: (a) obtaining a biological sample from the patient; (b) contacting the sample with an oligonucleotide probe specific for a DNA sequence encoding the above polypeptides; and (c) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe.
• the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA sequence encoding the above polypeptides.
• the present invention provides antibodies, both polyclonal and monoclonal, that bind to the polypeptides described above, as well as methods for their use in the detection of Ehrlichia infection.
• the present invention provides methods for detecting either Ehrlichia infection, Lyme disease or B. microti infection in a patient.
• inventive methods comprise (a) obtaining a biological sample from the patient; (b) contacting the sample with (i) at least one of the inventive polypeptides, antigenic epitopes or fusion proteins, (ii) a known Lyme disease antigen and (iii) a known B. microti antigen; and (b) detecting in the sample the presence of antibodies that bind to the inventive polypeptide, antigenic epitope or fusion protein, the known Lyme disease antigen or the known B. microti antigen, thereby detecting either Ehrlichia infection, Lyme disease or B. microti infection in the patient.
• the present invention provides pharmaceutical compositions that comprise one or more of the above polypeptides or antigenic epitopes, or a DNA molecule encoding such polypeptides, and a physiologically acceptable carrier.
• the invention also provides vaccines comprising one or more of the inventive polypeptides or antigenic epitopes and a non-specific immune response enhancer, together with vaccines comprising one or more DNA sequences encoding such polypeptides and a non-specific immune response enhancer.
• methods are provided for inducing protective immunity in a patient, comprising administering to a patient an effective amount of one or more of the above pharmaceutical compositions or vaccines.
• Fig. 1 shows the results of Western blot analysis of representative
• Fig. 2 A and B show the reactivity of purified recombinant Ehrlichia antigens HGE-1 and HGE-3, respectively, with sera from HGE-infected patients, babesiosis-infected patients, Lyme-disease infected patients and normal donors as determined by Western blot analysis.
• SEQ ID NO: 1 is the determined DNA sequence of HGE-1.
• SEQ ID NO: 2 is the determined DNA sequence of HGE-3.
• SEQ ID NO: 3 is the determined DNA sequence of HGE-6.
• SEQ ID NO: 4 is the determined 5' DNA sequence of HGE-7.
• SEQ ID NO : 5 is the determined DNA sequence of HGE- 12.
• SEQ ID NO: 6 is the determined DNA sequence of HGE-23.
• SEQ ID NO: 7 is the determined DNA sequence of HGE-24.
• SEQ ID NO: 8 is the predicted protein sequence of HGE-1.
• SEQ ID NO: 9 is the predicted protein sequence of HGE-3.
• SEQ ID NO: 10 is the predicted protein sequence of HGE-6.
• SEQ ID NO: 11 is the predicted protein sequence of HGE-7.
• SEQ ID NO: 12 is the predicted protein sequence of HGE-12.
• SEQ ID NO: 13 is the predicted protein sequence of HGE-23.
• SEQ ID NO: 14 is the predicted protein sequence of HGE-24.
• SEQ ID NO: 15 is the determined 5 ' DNA sequence of HGE-2.
• SEQ ID NO: 16 is the determined DNA sequence of HGE-9.
• SEQ ID NO: 17 is the determined DNA sequence of HGE-14.
• SEQ ID NO: 18 is the determined 5' DNA sequence of HGE- 15.
• SEQ ID NO: 19 is the determined 5' DNA sequence of HGE- 16.
• SEQ ID NO: 20 is the determined 5' DNA sequence of HGE- 17.
• SEQ ID NO: 21 is the determined 5' DNA sequence of HGE-18.
• SEQ ID NO: 22 is the determined 5' DNA sequence of HGE-25.
• SEQ ID NO: 23 is the predicted protein sequence of HGE-2.
• SEQ ID NO: 24 is the predicted protein sequence of HGE-9.
• SEQ ID NO: 25 is the predicted protein sequence of HGE-14.
• SEQ ID NO: 26 is the predicted protein sequence of HGE-18.
• SEQ ID NO: 27 is the predicted protein sequence from the reverse complement of HGE-14.
• SEQ ID NO: 28 is the predicted protein sequence from the reverse complement of HGE- 15.
• SEQ ID NO: 29 is the predicted protein sequence from the reverse complement of HGE- 18.
• SEQ ID NO: 30 is a 41 amino acid repeat sequence from HGE-14.
• SEQ ID NO: 31 is the determined DNA sequence of HGE-11.
• SEQ ID NO: 32 is the predicted protein sequence of HGE-11.
• SEQ ID NO: 33 is the predicted protein sequence from the reverse complement of HGE-11.
• SEQ ID NO: 34 is the determined DNA sequence of HGE-13.
• SEQ ID NO: 35 is the predicted protein sequence of HGE-13.
• SEQ ID NO: 36 is the determined DNA sequence of HGE-8.
• SEQ ID NO: 37 is the predicted protein sequence of HGE-8.
• SEQ ID NO: 38 is the predicted protein sequence from the reverse complement of HGE-8.
• SEQ ID NO: 39 is the extended DNA sequence of HGE-2.
• SEQ ID NO: 40 is the extended DNA sequence of HGE-7.
• SEQ ID NO: 41 is the extended DNA sequence of HGE-8.
• SEQ ID NO: 42 is the extended DNA sequence of HGE-11.
• SEQ ID NO: 43 is the extended DNA sequence of HGE-14.
• SEQ ID NO: 44 is the extended DNA sequence of HGE-15.
• SEQ ID NO: 45 is the extended DNA sequence of HGE- 16.
• SEQ ID NO: 46 is the extended DNA sequence of HGE- 18.
• SEQ ID NO: 47 is the extended DNA sequence of HGE-23.
• SEQ ID NO: 48 is the extended DNA sequence of HGE-25.
• SEQ ID NO: 49 is the determined 3' DNA sequence of HGE- 17.
• SEQ ID NO: 50 is the extended predicted protein sequence of HGE-2.
• SEQ ID NO: 51 is the amino acid repeat sequence of HGE-2.
• SEQ ID NO: 52 is a second predicted protein sequence of HGE-7.
• SEQ ID NO: 53 is a third predicted protein sequence of HGE-7.
• SEQ ID NO: 54 is a second predicted protein sequence of HGE-8.
• SEQ ID NO: 55 is a third predicted protein sequence of HGE-8.
• SEQ ID NO: 56 is a fourth predicted protein sequence of HGE-8.
• SEQ ID NO: 57 is a fifth predicted protein sequence of HGE-8.
• SEQ ID NO: 58 is a second predicted protein sequence of HGE-11.
• SEQ ID NO: 59 is a third predicted protein sequence of HGE-11.
• SEQ ID NO: 60 is a second predicted protein sequence from the reverse complement of HGE-14.
• SEQ ID NO: 61 is a third predicted protein sequence from the reverse complement of HGE-14.
• SEQ ID NO: 62 is a first predicted protein sequence of HGE- 15.
• SEQ ID NO: 63 is a second predicted protein sequence of HGE- 15.
• SEQ ID NO: 64 is a second predicted protein sequence from the reverse complement of HGE- 15.
• SEQ ID NO: 65 is the predicted protein sequence of HGE-16.
• SEQ ID NO: 66 is a first predicted protein sequence from the reverse complement of HGE- 17.
• SEQ ID NO: 67 is a second predicted protein sequence from the reverse complement of HGE- 17.
• SEQ ID NO: 68 is a second predicted protein sequence from the reverse complement of HGE- 18.
• SEQ ID NO: 69 is a third predicted protein sequence from the reverse complement of HGE- 18.
• SEQ ID NO: 70 is a fourth predicted protein sequence from the reverse complement of HGE- 18.
• SEQ ID NO: 71 is a second predicted protein sequence of HGE-23.
• SEQ ID NO: 72 is a third predicted protein sequence of HGE-23.
• SEQ ID NO: 73 is the predicted protein sequence of HGE-25.
• SEQ ID NO: 74-79 are primers used in the preparation of a fusion protein containing HGE-9, HGE-3 and HGE-1.
• SEQ ID NO: 80-83 are primers used in the preparation of a fusion protein containing HGE-3 and HGE-1 (referred to as ErF-1).
• SEQ ID NO: 84 is the DNA sequence of the fusion ErF-1.
• SEQ ID NO: 85 is the amino acid sequence of the fusion protein ErF-1. DETAILED DESCRIPTION OF THE INVENTION
• compositions and methods for the diagnosis and treatment of Ehrlichia infection in particular HGE.
• the compositions of the subject invention include polypeptides that comprise at least one immunogenic portion of an Ehrlichia antigen, or a variant of such an antigen that differs only in conservative substitutions and/or modifications.
• polypeptide encompasses amino acid chains of any length, including full length proteins ( . e. , antigens), wherein the amino acid residues are linked by covalent peptide bonds.
• a polypeptide comprising an immunogenic portion of one of the above antigens may consist entirely of the immunogenic portion, or may contain additional sequences.
• the additional sequences may be derived from the native Ehrlichia antigen or may be heterologous, and such sequences may (but need not) be immunogenic.
• an "immunogenic portion" of an antigen is a portion that is capable of reacting with sera obtained from an Ehrlichia-infected individual (i.e., generates an absorbance reading with sera from infected individuals that is at least three standard deviations above the absorbance obtained with sera from uninfected individuals, in a representative ELISA assay described herein).
• Such immunogenic portions generally comprise at least about 5 amino acid residues, more preferably at least about 10, and most preferably at least about 20 amino acid residues.
• Methods for preparing and identifying immunogenic portions of antigens of known sequence are well known in the art and include those summarized in Paul, Fundamental Immunology, 3 rd ed., Raven Press, 1993, pp. 243-247.
• Polypeptides comprising at least an immunogenic portion of one or more Ehrlichia antigens as described herein may generally be used, alone or in combination, to detect HGE in a patient.
• compositions and methods of the present invention also encompass variants of the above polypeptides and DNA molecules.
• variants include, but are not limited to, naturally occurring allelic variants of the inventive sequences.
• a polypeptide "variant,” as used herein, is a polypeptide that differs from the recited polypeptide only in conservative substitutions and/or modifications, such that the antigenic properties of the polypeptide are retained.
• variant polypeptides differ from an identified sequence by substitution, deletion or addition of five amino acids or fewer.
• Such variants may generally be identified by modifying one of the above polypeptide sequences, and evaluating the antigenic properties of the modified polypeptide using, for example, the representative procedures described herein.
• Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% identity (determined as described below) to the identified polypeptides.
• a "conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged.
• the following groups of amino acids represent conservative changes: (l) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met. ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.
• Variants may also, or alternatively, contain other modifications, including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and hydropathic nature of the polypeptide.
• a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein.
• the polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His). or to enhance binding of the polypeptide to a solid support.
• a polypeptide may be conjugated to an immunoglobulin Fc region.
• nucleotide “variant” is a sequence that differs from the recited nucleotide sequence in having one or more nucleotide deletions, substitutions or additions. Such modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. ⁇ DNA, 2:183, 1983). Nucleotide variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant nucleotide sequences preferably exhibit at least about 70%, more preferably at least about 80%) and most preferably at least about 90% identity (determined as described below) to the recited sequence.
• Two nucleotide or polypeptide sequences are said to be “identical” if the sequence of nucleotides or amino acid residues in the two sequences is the same when aligned for maximum correspondence as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity.
• a “comparison window” as used herein refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
• Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters.
• This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins - Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Resarch Foundaiton, Washington DC Vol. 5, Suppl. 3, pp. 345- 358; Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645 Methods in Enzymology vol.
• the "percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e. gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences.
• the percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e. the window size) and multiplying the results by 100 to yield the percentage of sequence identity.
• the subject invention discloses polypeptides comprising at least an immunogenic portion of an Ehrlichia antigen (or a variant of such an antigen), that comprises one or more of the amino acid sequences encoded by (a) a DNA sequence selected from the group consisting of SEQ ID NO: 1-3, 5, 7, 16, 20, 34, 39-49, (b) the complements of such DNA sequences or (c) DNA sequences substantially homologous to a sequence in (a) or (b).
• the Ehrlichia antigens provided by the present invention include variants that are encoded by DNA sequences which are substantially homologous to one or more of the DNA sequences specifically recited herein.
• “Substantial homology,” as used herein, refers to DNA sequences that are capable of hybridizing under moderately stringent conditions. Suitable moderately stringent conditions include prewashing in a solution of 5X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5X SSC, overnight or, in the event of cross-species homology, at 45°C with 0.5X SSC; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS.
• hybridizing DNA sequences are also within the scope of this invention, as are nucleotide sequences that, due to code degeneracy, encode an immunogenic polypeptide that is encoded by a hybridizing DNA sequence.
• Ehrlichia antigens and DNA sequences encoding such antigens, may be prepared using any of a variety of procedures.
• DNA molecules encoding Ehrlichia antigens may be isolated from an Ehrlichia genomic or cDNA expression library by screening with sera from HGE-infected individuals as described below in Example 1 , and sequenced using techniques well known to those of skill in the art.
• DNA molecules encoding Ehrlichia antigens may also be isolated by screening an appropriate Ehrlichia expression library with anti-sera ⁇ e.g., rabbit) raised specifically against Ehrlichia antigens.
• Antigens may be induced from such clones and evaluated for a desired property, such as the ability to react with sera obtained from an HGE-infected individual as described herein.
• antigens may be produced recombinantly, as described below, by inserting a DNA sequence that encodes the antigen into an expression vector and expressing the antigen in an appropriate host.
• Antigens may be partially sequenced using, for example, traditional Edman chemistry. See Edman and Berg, Eur. J. Biochem. 80: ⁇ 16-132, 1967.
• DNA sequences encoding antigens may also be obtained by screening an appropriate Ehrlichia cDNA or genomic DNA library for DNA sequences that hybridize to degenerate oligonucleotides derived from partial amino acid sequences of isolated antigens.
• Degenerate oligonucleotide sequences for use in such a screen may be designed and synthesized, and the screen may be performed, as described (for example) in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (and references cited therein).
• PCR Polymerase chain reaction
• oligonucleotides in methods well known in the art, to isolate a nucleic acid probe from a cDNA or genomic library.
• the library screen may then be performed using the isolated probe.
• Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids may be generated using techniques well known in the art.
• such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 55:2149-2146, 1963.
• Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/ Applied BioSystems Division, Foster City, CA, and may be operated according to the manufacturer's instructions.
• Immunogenic portions of Ehrlichia antigens may be prepared and identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3d ed., Raven Press, 1993, pp. 243-247 and references cited therein. Such techniques include screening polypeptide portions of the native antigen for immunogenic properties.
• the representative ELI S As described herein may generally be employed in these screens.
• An immunogenic portion of a polypeptide is a portion that, within such representative assays, generates a signal in such assays that is substantially similar to that generated by the full length antigen.
• an immunogenic portion of an Ehrlichia antigen generates at least about 20%, and preferably about 100%, of the signal induced by the full length antigen in a model ELISA as described herein.
• Portions and other variants of Ehrlichia antigens may be generated by synthetic or recombinant means.
• Variants of a native antigen may generally be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis. Sections of the DNA sequence may also be removed using standard techniques to permit preparation of truncated polypeptides.
• Recombinant polypeptides containing portions and/or variants of a native antigen may be readily prepared from a DNA sequence encoding the polypeptide using a variety of techniques well known to those of ordinary skill in the art. For example, supernatants from suitable host/vector systems which secrete recombinant protein into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant protein.
• a suitable purification matrix such
• Any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides as described herein. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line, such as COS or CHO. The DNA sequences expressed in this manner may encode naturally occurring antigens, portions of naturally occurring antigens, or other variants thereof.
• the present invention provides antigenic epitopes of an Ehrlichia antigen or epitope repeat sequences, as well as polypeptides comprising at least two such contiguous antigenic epitopes.
• an "epitope" is a portion of an antigen that reacts with sera from Ehrlichia-infected individuals (i.e. an epitope is specifically bound by one or more antibodies present in such sera).
• epitopes of the antigens described in the present application may be generally identified using techniques well known to those of skill in the art.
• antigenic epitopes of the present invention comprise an amino acid sequence selected from the group consisting of sequence recited in SEQ ID NO: 30 and 51.
• antigenic epitopes provided herein may be employed in the diagnosis and treatment of Ehrlichia infection, either alone or in combination with other Ehrlichia antigens or antigenic epitopes.
• Antigenic epitopes and polypeptides comprising such epitopes may be prepared by synthetic means, as described generally above and in detail in Example 3.
• the polypeptides and antigenic epitopes disclosed herein are prepared in an isolated, substantially pure, form.
• the polypeptides and antigenic epitopes are at least about 80% pure, more preferably at least about 90% pure and most preferably at least about 99% pure.
• the present invention provides fusion proteins comprising either a first and a second inventive polypeptide, a first and a second inventive antigenic epitope, or an inventive polypeptide and an antigenic epitope of the present invention, together with variants of such fusion proteins.
• the fusion proteins of the present invention may also include a linker peptide between the polypeptides or antigenic epitopes.
• a DNA sequence encoding a fusion protein of the present invention may be constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding, for example, the first and second polypeptides, into an appropriate expression vector.
• the 3' end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to permit mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and the second polypeptides.
• a peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art.
• Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes.
• Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence.
• Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci.
• the linker sequence may be from 1 to about 50 amino acids in length.
• a peptide linker sequence when desired, one can utilize non-essential N-terminal amino acid regions (when present) on the first and second polypeptides to separate the functional domains and prevent steric hindrance.
• the present invention provides methods for using the polypeptides, fusion proteins and antigenic epitopes described above to diagnose Ehrlichia infection, in particular HGE.
• methods are provided for detecting Ehrlichia infection in a biological sample, using one or more of the above polypeptides, fusion proteins and antigenic epitopes, either alone or in combination.
• polypeptide will be used when describing specific embodiments of the inventive diagnostic methods.
• antigenic epitopes and fusion proteins of the present invention may also be employed in such methods.
• a "biological sample” is any antibody-containing sample obtained from a patient.
• the sample is whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid or urine. More preferably, the sample is a blood, serum or plasma sample obtained from a patient.
• the polypeptides are used in an assay, as described below, to determine the presence or absence of antibodies to the polypeptide(s) in the sample, relative to a predetermined cut-off value. The presence of such antibodies indicates previous sensitization to Ehrlichia antigens which may be indicative of HGE.
• the polypeptides used are preferably complementary (i.e., one component polypeptide will tend to detect infection in samples where the infection would not be detected by another component polypeptide).
• Complementary polypeptides may generally be identified by using each polypeptide individually to evaluate serum samples obtained from a series of patients known to be infected with HGE. After determining which samples test positive (as described below) with each polypeptide, combinations of two or more polypeptides may be formulated that are capable of detecting infection in most, or all, of the samples tested.
• the assay involves the use of polypeptide immobilized on a solid support to bind to and remove the antibody from the sample. The bound antibody may then be detected using a detection reagent that contains a reporter group. Suitable detection reagents include antibodies that bind to the antibody/polypeptide complex and free polypeptide labeled with a reporter group (e.g., in a semi- competitive assay).
• a competitive assay may be utilized, in which an antibody that binds to the polypeptide is labeled with a reporter group and allowed to bind to the immobilized antigen after incubation of the antigen with the sample.
• the extent to which components of the sample inhibit the binding of the labeled antibody to the polypeptide is indicative of the reactivity of the sample with the immobilized polypeptide.
• the solid support may be any solid material known to those of ordinary skill in the art to which the antigen may be attached.
• the solid support may be a test well in a microtiter plate, or a nitrocellulose or other suitable membrane.
• the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride.
• the support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681.
• polypeptides may be bound to the solid support using a variety of techniques known to those of ordinary skill in the art.
• bound refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross- linking agent). Binding by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and 1 day.
• contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of polypeptide ranging from about 10 ng to about 1 ⁇ g, and preferably about 100 ng, is sufficient to bind an adequate amount of antigen.
• a plastic microtiter plate such as polystyrene or polyvinylchloride
• Covalent attachment of polypeptide to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the polypeptide.
• a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the polypeptide.
• the polypeptide may be bound to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the polypeptide (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).
• the assay is an enzyme linked immunosorbent assay (ELISA).
• ELISA enzyme linked immunosorbent assay
• This assay may be performed by first contacting a polypeptide antigen that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that antibodies to the polypeptide within the sample are allowed to bind to the immobilized polypeptide. Unbound sample is then removed from the immobilized polypeptide and a detection reagent capable of binding to the immobilized antibody-polypeptide complex is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific detection reagent.
• the polypeptide is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin (BSA) or Tween 20TM (Sigma Chemical Co., St. Louis, MO) may be employed.
• BSA bovine serum albumin
• Tween 20TM Sigma Chemical Co., St. Louis, MO
• the immobilized polypeptide is then incubated with the sample, and antibody is allowed to bind to the antigen.
• the sample may be diluted with a suitable dilutent, such as phosphate-buffered saline (PBS) prior to incubation.
• PBS phosphate-buffered saline
• an appropriate contact time i. e. , incubation time
• incubation time is that period of time that is sufficient to detect the presence of antibody within an HGE-infected sample.
• the contact time is sufficient to achieve a level of binding that is at least 95% of that achieved at equilibrium between bound and unbound antibody.
• the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.
• Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20TM.
• Detection reagent may then be added to the solid support.
• An appropriate detection reagent is any compound that binds to the immobilized antibody-polypeptide complex and that can be detected by any of a variety of means known to those in the art.
• the detection reagent contains a binding agent (such as, for example, Protein A, Protein G, immunoglobulin, lectin or free antigen) conjugated to a reporter group.
• Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin.
• binding agent to reporter group may be achieved using standard methods known to those of ordinary skill in the art. Common binding agents may also be purchased conjugated to a variety of reporter groups from many commercial sources ⁇ e.g., Zymed Laboratories, San Francisco, CA, and Pierce, Rockford, IL).
• the detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound antibody.
• An appropriate amount of time may generally be determined from the manufacturer's instructions or by assaying the level of binding that occurs over a period of time.
• Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group.
• the method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.
• the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value.
• the cut-off value is the average mean signal obtained when the immobilized antigen is incubated with samples from an uninfected patient.
• a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for HGE.
• the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, Little Brown and Co., 1985, pp. 106-107.
• the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result.
• the cut-off value on the plot that is the closest to the upper left-hand corner i.e., the value that encloses the largest area
• a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive.
• the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate.
• a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for HGE.
• the assay is performed in a rapid flow- through or strip test format, wherein the antigen is immobilized on a membrane, such as nitrocellulose.
• a membrane such as nitrocellulose.
• a detection reagent e.g., protein A-colloidal gold
• a detection reagent then binds to the antibody-polypeptide complex as the solution containing the detection reagent flows through the membrane.
• the detection of bound detection reagent may then be performed as described above.
• the strip test format one end of the membrane to which polypeptide is bound is immersed in a solution containing the sample.
• the sample migrates along the membrane through a region containing detection reagent and to the area of immobilized polypeptide.
• Concentration of detection reagent at the polypeptide indicates the presence of anti-Ehrlichia antibodies in the sample.
• concentration of detection reagent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result.
• the amount of polypeptide immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of antibodies that would be sufficient to generate a positive signal in an ELISA, as discussed above.
• the amount of polypeptide immobilized on the membrane ranges from about 25 ng to about 1 ⁇ g, and more preferably from about 50 ng to about 500 ng.
• Such tests can typically be performed with a very small amount (e.g., one drop) of patient serum or blood.
• inventive polypeptides may be employed in combination with known Lyme disease and/or B. microti antigens to diagnose the presence of either Ehrlichia infection, Lyme disease and/or B. microti infection, using either the assay formats described herein or other assay protocols.
• One example of an alternative assay protocol which may be usefully employed in such methods is a Western blot, wherein the proteins present in a biological sample are separated on a gel, prior to exposure to a binding agent.
• Lyme disease antigens which may be usefully employed in such methods are well known to those of skill in the art and include, for example, those described by Magnarelli, L. et al. (J. Clin.
• microti antigens which may be usefully employed in the inventive methods include those described in U.S. Patent Application No. 08/845,258, filed April 24, 1997, the disclosure of which is hereby incorporated by reference.
• the present invention provides antibodies to the polypeptides and antigenic epitopes of the present invention.
• Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988.
• an immunogen comprising the antigenic polypeptide or epitope is initially injected into any of a wide variety of mammals ⁇ e.g., mice, rats, rabbits, sheep and goats).
• the polypeptides and antigenic epitopes of this invention may serve as the immunogen without modification.
• a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin.
• the immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically.
• Polyclonal antibodies specific for the polypeptide or antigenic epitope may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.
• Monoclonal antibodies specific for the antigenic polypeptide or epitope of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. (5:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide or antigenic epitope of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed.
• the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells.
• a preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide or antigenic epitope. Hybridomas having high reactivity and specificity are preferred.
• Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies.
• various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse.
• Monoclonal antibodies may then be harvested from the ascites fluid or the blood.
• Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction.
• the polypeptides or antigenic epitopes of this invention may be used in the purification process in, for example, an affinity chromatography step.
• Antibodies may be used in diagnostic tests to detect the presence of Ehrlichia antigens using assays similar to those detailed above and other techniques well known to those of skill in the art, thereby providing a method for detecting Ehrlichia infection in a patient.
• Diagnostic reagents of the present invention may also comprise DNA sequences encoding one or more of the above polypeptides, or one or more portions thereof.
• at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify Ehrlichia-specific cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for a DNA molecule encoding a polypeptide of the present invention.
• PCR polymerase chain reaction
• oligonucleotide probes specific for a DNA molecule encoding a polypeptide of the present invention may be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample.
• oligonucleotide primer/probe specific for a DNA molecule means an oligonucleotide sequence that has at least about 80%, preferably at least about 90% and more preferably at least about 95%, identity to the DNA molecule in question. Oligonucleotide primers and/or probes which may be usefully employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the oligonucleotide primers comprise at least about 10 contiguous nucleotides of a DNA molecule encoding one of the polypeptides disclosed herein.
• oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a DNA molecule encoding one of the polypeptides disclosed herein.
• Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al. Ibid; Ehrlich, Ibid). Primers or probes may thus be used to detect Ehrlichia-specific sequences in biological samples.
• DNA probes or primers comprising oligonucleotide sequences described above may be used alone or in combination with each other.
• the present invention provides methods for using one or more of the above polypeptides, antigenic epitopes or fusion proteins (or DNA molecules encoding such polypeptides) to induce protective immunity against Ehrlichia infection in a patient.
• a "patient” refers to any warmblooded animal, preferably a human.
• a patient may be afflicted with a disease, or may be free of detectable disease and/or infection.
• protective immunity may be induced to prevent or treat Ehrlichia infection, specifically HGE.
• the polypeptide, antigenic epitope, fusion protein or DNA molecule is generally present within a pharmaceutical composition or a vaccine.
• Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier.
• Vaccines may comprise one or more of the above polypeptides and a non-specific immune response enhancer, such as an adjuvant or a liposome (into which the polypeptide is incorporated).
• Such pharmaceutical compositions and vaccines may also contain other Ehrlichia antigens, either incorporated into a combination polypeptide or present within a separate polypeptide.
• a vaccine may contain DNA encoding one or more polypeptides, antigenic epitopes or fusion proteins as described above, such that the polypeptide is generated in situ.
• the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal).
• Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerri ⁇ ) that expresses an immunogenic portion of the polypeptide on its cell surface.
• the DNA may be introduced using a viral expression system ⁇ e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), virus.
• a viral expression system e.g., vaccinia or other pox virus, retrovirus, or adenovirus
• vaccinia or other pox virus e.g., vaccinia or other pox virus, retrovirus, or adenovirus
• a non-pathogenic virus e.g., vaccinia or other pox virus, retrovirus, or adenovirus
• a DNA vaccine as described above may be administered simultaneously with or sequentially to either a polypeptide of the present invention or a known Ehrlichia antigen.
• administration of DNA encoding a polypeptide of the present invention may be followed by administration of an antigen in order to enhance the protective immune effect of the vaccine.
• compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 3 doses may be administered for a 1-36 week period. Preferably, 3 doses are administered, at intervals of 3-4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients.
• a suitable dose is an amount of polypeptide or DNA that, when administered as described above, is capable of raising an immune response in an immunized patient sufficient to protect the patient from HGE for at least 1-2 years.
• the amount of polypeptide present in a dose ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 ⁇ g.
• Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.
• any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration.
• the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer.
• any of the above carriers or a solid carrier such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed.
• Biodegradable microspheres e.g., polylactic galactide
• Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.
• adjuvants may be employed in the vaccines of this invention to nonspecifically enhance the immune response.
• Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a nonspecific stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis.
• Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories, Detroit, MI) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ).
• Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A and quil A. The following Examples are offered by way of illustration and not by way of limitation. EXAMPLE 1 ISOLATION OF DNA SEQUENCES ENCODING EHRLICHIA ANTIGENS
• This example illustrates the preparation of DNA sequences encoding Ehrlichia antigens by screening an Ehrlichia genomic expression library with sera obtained from mice infected with the HGE agent.
• Ehrlichia genomic DNA was isolated from infected human HL60 cells and sheared by sonication. The resulting randomly sheared DNA was used to construct an Ehrlichia genomic expression library (approximately 0.5 - 4.0 kbp inserts) with EcoRI adaptors and a Lambda ZAP II/EcoRI/CIAP vector (Stratagene, La Jolla, CA). The unamplif ⁇ ed library (6.5 x lOVml) was screened with an E. coli lysate-absorbed Ehrlichia mouse serum pool, as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989.
• Positive plaques were visualized and purified with goat- anti-mouse alkaline phosphatase. Phagemid from the plaques was rescued and DNA sequence for positive clones was obtained using forward, reverse, and specific internal primers on a Perkin Elmer/Applied Biosystems Inc. Automated Sequencer Model 373 A (Foster City, CA).
• HG ⁇ -1, HGE-3, HGE-6, HGE-7, HGE-12, HGE-23 and HGE-24 seven (hereinafter referred to as HG ⁇ -1, HGE-3, HGE-6, HGE-7, HGE-12, HGE-23 and HGE-24) were found to be related.
• the determined DNA sequences for HGE-1, HGE-3, HGE-6, HGE-12, HGE-23 and HGE-24 are shown in SEQ ID NO: 1-3 and 5-7, respectively, with the 5' DNA sequence for HGE-7 being provided in SEQ ID NO: 4.
• the deduced amino acid sequences for HGE-1, HGE-3, HGE-6, HGE-7, HGE-12, HGE-23 and HGE-24 are provided in SEQ ID NO: 8-14, respectively. Comparison of these sequences with known sequences in the gene bank using the DNA STAR system, revealed some degree of homology to the Anaplasma marginale major surface protein.
• HGE-2, HGE-9, HGE-14, HGE-15, HGE-16, HGE-17, HGE-18 and HGE-25 are determined full-length DNA sequences for HGE-9 and HGE-14, respectively, with the determined 5' DNA sequences for HGE-2, HGE-15, HGE-16, HGE-17, HGE-18 and HGE-25 being shown in SEQ ID NO: 15, and 18-22, respectively.
• the corresponding predicted amino acid sequences for HGE-2, HGE-9, HGE-14 and HGE-18 are provided in SEQ ID NO: 23-26, respectively.
• HGE-14, HGE-15 and HGE-18 were found to contain open reading frames which encode the amino acid sequences shown in SEQ ID NO: 27, 28 and 29, respectively.
• the predicted amino acid sequence from the reverse complement strand of HGE-14 (SEQ ID NO: 27) was found to contain a 41 amino acid repeat, provided in SEQ ID NO: 30.
• the determined DNA sequence for the isolated antigen HGE-11 is provided in SEQ ID NO: 31, with the predicted amino acid sequences being provided in SEQ ID NO: 32 and 33. Comparison of these sequences with known sequence in the gene bank, revealed some homology between the amino acid sequence of SEQ ID NO: 32 and that of bacterial DNA-directed RNA polymerase beta subunit rpoB (Monastyrskaya, G.S.
• the determined 5' DNA sequence for the antigen HGE-13 is provided in SEQ ID NO: 34.
• the opposite strand for HGE- 13 was found to contain an open reading frame which encodes the amino acid sequence provided in SEQ ID NO: 35. This sequence was found to have some homology to bacterial 2,3- biphosphoglycerate-independent phosphoglycerate mutase (Leyva- Vazquez, M. A. and Setlow, P., 1994 J Bacteriol. 176:3903-3910).
• the determined partial nucleotide sequence for the isolated antigen is provided in SEQ ID NO: 34.
• the opposite strand for HGE- 13 was found to contain an open reading frame which encodes the amino acid sequence provided in SEQ ID NO: 35. This sequence was found to have some homology to bacterial 2,3- biphosphoglycerate-independent phosphoglycerate mutase (Leyva- Vazquez, M. A. and Setlow, P., 1994 J Bacteriol. 176
• HGE-8 (SEQ ID NO: 36) was found to include, on the reverse complement of the 5' end, two open reading frames encoding the amino acid sequences provided in SEQ ID NO: 37 and 38.
• the amino acid sequences of SEQ ID NO: 37 and 38 were found to show some homology to prokaryotic and eukaryotic dihydrolipamide succinyltransferase (Fleischmann R.D. et al, 1995 Science 269:496-512) and methionine aminopeptidase (Chang, Y.H., 1992 J. Biol. Chem. 2(57:8007-801 1), respectively.
• the extended DNA sequence of HGE-8 was found to contain four open reading frames encoding the proteins of SEQ ID NO: 54-57. Each of these four proteins was found to show some similarity to known proteins, however, to the best of the inventors' knowledge, none have previously been identified in Ehrlichia.
• the extended DNA sequence of HGE-11 was found to contain two open reading frames encoding for the amino acid sequences provided in SEQ ID NO: 58 and 59. These two proteins were found to show some homology to the bacterial DNA-directed RNA polymerase beta subunits rpoB and rpo C, respectively.
• the reverse complement of the extended DNA sequence of HGE-14 was found to contain two open reading frames, with one encoding the amino acid sequence provided in SEQ ID NO: 60.
• the second open reading frame encodes the amino acid sequence provided in SEQ ID NO: 61, which contains the amino acid sequence provided in SEQ ID NO: 27.
• the extended DNA sequence of HGE-15 was found to contain two open reading frames encoding for the sequences provided in SEQ ID NO: 62 and 63, with a third open reading frame encoding the sequence of SEQ ID NO: 64 being located on the reverse complement.
• the extended DNA sequence of HGE-16 was found to contain an open reading frame encoding the amino acid sequence of SEQ ID NO: 65.
• the reverse complement of the 3' DNA sequence of HGE-17 was found to contain two open reading frames encoding the amino acid sequences of SEQ ID NO: 66 and 67.
• the reverse complement of the extended DNA sequence of HGE-18 was found to contain three open reading frames encoding the amino acid sequences of SEQ ID NO: 68-70.
• the sequence of SEQ ID NO: 70 was found to show some homology to bacterial DNA helicase.
• the extended DNA sequence of HGE-23 was found to contain two open reading frames encoding for the sequences of SEQ ID NO:71 and 72. Both of these sequences, together with those of SEQ ID NO:52 and 53, were found to share some homology with the Anaplasma marginale major surface protein.
• the predicted amino acid sequence for the extended DNA sequence of HGE- 25 is provided in SEQ ID NO:73. This sequence was found to show some similarity to that of SEQ ID NO:64 (HGE-15). No significant homologies were found to the sequences of HGE-2, HGE-14, HGE-15, HGE-16, HGE-17 and HGE-25 (SEQ ID NO: 50, 60-67 and 73).
• Antigens were induced as pBluescript SK- constructs (Stratagene), with 2 mM IPTG for three hours (T3), after which the resulting proteins from time 0 (TO) and T3 were separated by SDS-PAGE on 15% gels. Separated proteins were then transferred to nitrocellulose and blocked for 1 hr in 1% BSA in 0.1 % Tween 20TM/PBS. Blots were then washed 3 times in 0.1% Tween 20TM/PBS and incubated with either an HGE patient serum pool (1 :200) or an Ehrlichia-m ' fccted mouse serum pool for a period of 2 hours.
• blots were incubated with a second antibody (goat-anti -human IgG conjugated to alkaline phosphatase (AP) or goat-anti-mouse IgG-AP, respectively) for 1 hour. Immunocomplexes were visualized with NBT/BCIP (Gibco BRL) after washing with Tween 20TM/PBS three times and AP buffer (100 mM Tris-HCl, 100 mM Na CI, 5 mM MgCl 2 , pH 9.5) two times.
• AP buffer 100 mM Tris-HCl, 100 mM Na CI, 5 mM MgCl 2 , pH 9.5
• resulting bands of reactivity with serum antibody were seen at 37 kDa for HGE-1 and HGE-3 for both the mouse serum pool and the human serum pool.
• Protein size standards in kDa (Gibco BRL, Gaithersburg, MD), are shown to the left of the blots.
• Western blots were performed on partially purified HGE-1 and HGE-3 recombinant antigen with a series of patient sera from HGE patients, patients with Lyme disease, babesiosis patients or from normal donors. Specifically, purified antigen (4 ⁇ g) was separated by SDS-PAGE on 12% gels. Protein was then transferred to nitrocellulose membrane for immunoblot analysis. The membrane was first blocked with PBS containing 1% Tween 20TM for 2 hours. Membranes were then cut into strips and incubated with individual sera (1/500) for two hours.
• HGE-1 MW 37 kD
• HGE-3 MW 37 kD
• cross-reactivity was seen with sera from two of the five babesiosis patients and weak cross-reactivity was seen with sera from two of the five Lyme disease patients.
• This apparent cross-reactivity may represent the ability of the antigen HGE-3 to detect low antibody titer in patients co-infected with HGE. No immunoreactivity of HGE-3 was seen with sera from normal patients.
• Table 1 provides representative data from studies of the reactivity of HGE-1, HGE-3 and HGE-9 with both IgG and IgM in sera from patients with acute (A) or convalescent (C) HGE, determined as described above.
• the antibody titer for each patient, as determined by immunofluorescence, is also provided.
• HGE-9 is able to complement the serological reactivity of HGE-1 and HGE-3, leading to increased sensitivity in the serodiagnosis of HGE-infection in convalescent and acute patient sera, as shown, for example, with patients 5, 8, 11 and 12 in Table 1.
• a fusion protein containing the Ehrlichia antigens HGE-9, HGE-3 and HGE-1 is prepared as follows.
• HGE-9, HGE-3 and HGE-1 are modified by PCR in order to facilitate their fusion and the subsequent expression of the fusion protein.
• HGE-9, HGE-3 and HGE-1 DNA was used to perform PCR using the primers PDM-225 and PDM-226 (SEQ ID NO: 74 and 75), PDM-227 and PDM-228 (SEQ ID NO: 76 and 77), and PDM-229 and PDM-209 (SEQ ID NO: 78 and 79), respectively.
• the DNA amplification is performed using 10 ⁇ l of lOx Pfu buffer (Stratagene), 1 ⁇ l of 12.5 mM dNTPs, 2 ⁇ l each of the PCR primers at 10 ⁇ M concentration, 82 ⁇ l water, 2 ⁇ l Pfu DNA polymerase (Stratagene, La Jolla, CA) and 1 ⁇ l DNA at 110 ng/ ⁇ l. Denaturation at 96°C is performed for 2 min, followed by 40 cycles of 96°C for 20 sec, 60°C for 15 sec and 72°C for 5 min, and lastly by 72 °C for 5 min.
• HGE-9 PCR fragment is cloned into pPDM HIS at the Eco 72 I sites along with a three-way ligation of HGE-3 or HGE-1 by cutting with Pvu I.
• HGE-3 is cloned into pPDM HIS which has been cut with Eco 721/Xho I.
• HGE-1 is cloned into pPDM HIS which has been cut with Eco 721/Eco RI.
• PCR is performed on the ligation mix of each fusion with the primers PDM-225, PDM-228 and PDM- 209 using the conditions provided above.
• PCR products are digested with Eco RI (for HGE-1) or Xho I (for HGE-3) and cloned into pPDM HIS which is digested with Eco RI (or Xho I) and Eco 721.
• the fusion construct is confirmed by DNA sequencing.
• the expression construct is transformed to BLR pLys S E. coli (Novagen, Madison, WI) and grown overnight in LB broth with kanamycin (30 ⁇ g/ml) and chloramphenicol (34 ⁇ g/ml). This culture (12 ml) is used to inoculate 500 ml 2XYT with the same antibiotics and the culture is induced with IPTG. Four hours post-induction, the bacteria are harvested and sonicated in 20 mM Tris (8.0), 100 mM NaCl, 0.1% DOC, followed by centrifugation at 26,000 X g.
• the resulting pellet is resuspended in 8 M urea, 20 mM Tris (8.0), 100 mM NaCl and bound to Ni NTA agarose resin (Qiagen, Chatsworth, CA).
• the column is washed several times with the above buffer then eluted with an imidazole gradient (50 mM, 100 mM, 500 mM imidazole is added to 8 M urea, 20 mM Tris (8.0), 100 mM NaCl).
• the eluates containing the protein of interest are then dialyzed against 10 mM Tris (8.0).
• HGE-3 and HGE-1 DNA was used to perform PCR using the primers PDM-263 and PDM-264 (SEQ ID NO: 80 and 81), and PDM-208 and PDM-265 (SEQ ID NO: 82 and 83), respectively.
• the DNA amplification was performed using 10 ⁇ l of lOx Pfu buffer (Stratagene), 1 ⁇ l of 10 mM dNTPs, 2 ⁇ l each of the PCR primers at 10 ⁇ M concentration, 83 ⁇ l water, 1.5 ⁇ l Pfu DNA polymerase (Stratagene, La Jolla, CA) and 1 ⁇ l DNA at 50 ng/ ⁇ l.
• Denaturation at 96 °C was performed for 2 min, followed by 40 cycles of 96°C for 20 sec, 60°C for 15 sec and 72°C for 3 min, and lastly by 72°C for 4 min.
• the HGE-3 PCR product was digested with Eco 721 and Xho I, and cloned into pPDM His which had been digested with Eco 721 and Xho I.
• the HGE-1 PCR product was digested with Seal, cloned into the above construct at the Seal site, and screened for orientation. The fusion construct was confirmed by DNA sequencing. The determined DNA sequence of the fusion construct is provided in SEQ ID NO: 84.
• the expression construct was transformed into BL21 pLys S E. coli (Novagen, Madison, WI) and grown overnight in LB broth with kanamycin (30 ⁇ g/ml) and chloramphenicol (34 ⁇ g/ml). This culture (12 ml) was used to inoculate 500 ml 2XYT with the same antibiotics and the culture was induced with IPTG. Four hours post-induction, the bacteria were harvested and sonicated in 20 mM Tris (8.0), 100 mM NaCl, 0.1% DOC, followed by centrifugation at 26,000 X g. The protein came out in the inclusion body pellet.
• This pellet was washed three times with a 0.5% CHAPS wash in 20 mM Tris (8.0), 300 mM NaCl. The pellet was then solubilized in 6 M GuHCl, 20 mM Tris (9.0), 300 mM NaCl, 1% Triton X-100 and batch bound to Nickel NTA resin (Qiagen). The column was washed with 100 ml 8M urea, 20 mM Tris (9.0), 300 mM NaCl and 1% DOC. This wash was repeated but without DOC. The protein was eluted with 8 M urea, 20 mM Tris (9.0), 100 mM NaCl and 500 mM imidazole.
• the imidazole was increased to IM.
• the elutions were run on a 4-20% SDS-PAGE gel and the fractions containing the protein of interest were pooled and dialyzed against 10 mM Tris (9.0).
• the amino acid sequence of the fusion protein ErF-1 is provided in SEQ ID NO: 85.
• One of skill in the art will appreciate that the order of the individual antigens within the fusion protein may be changed and that comparable or enhanced activity could be expected provided each of the epitopes is still functionally available.
• truncated forms of the proteins containing active epitopes may be used in the construction of fusion proteins.
• Table 2 provides representative data from studies of the reactivity of ErF-1, HGE-1 and HGE-3 with both IgG and IgM in sera from patients with acute (A) or convalescent (C) HGE, determined as described above in Example 2.
• the antibody titer for each patient, as determined by immunofluorescence, is also provided.
• Polypeptides may be synthesized on a Millipore 9050 peptide synthesizer using FMOC chemistry with HPTU (O-Benzotriazole-N,N,N',N'- tetramethyluronium hexafluorophosphate) activation.
• HPTU O-Benzotriazole-N,N,N',N'- tetramethyluronium hexafluorophosphate
• a Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of conjugating or labeling of the peptide.
• Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1 :2:2:3).
• the peptides may be precipitated in cold methyl-t-butyl-ether.
• the peptide pellets may then be dissolved in water containing 0.1 % trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC.
• TFA trifluoroacetic acid
• a gradient of 0-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1 % TFA) may be used to elute the peptides.
• the peptides may be characterized using electrospray mass spectrometry and by amino acid analysis.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Gastroenterology & Hepatology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Applications Claiming Priority (7)

Publications (2)

Family

ID=27380149

Family Applications (1)

Country Status (5)

Cited By (2)

Families Citing this family (16)

Family Cites Families (4)

• 1999
  • 1999-04-20 US US09/295,028 patent/US6277381B1/en not_active Expired - Lifetime
  • 1999-06-29 EP EP99932087A patent/EP1144639A3/de not_active Withdrawn
  • 1999-06-29 AU AU48474/99A patent/AU4847499A/en not_active Abandoned
  • 1999-06-29 WO PCT/US1999/014793 patent/WO2000000615A2/en not_active Application Discontinuation
  • 1999-06-29 CA CA002331845A patent/CA2331845A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events